Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective studyKallel, Lamiaa; Ayadi, Imenb; Matri, Samiraa; Fekih, Moniaa; Mahmoud, Nadia Bena; Feki, Moncefb; Karoui, Samia; Zouari, Bechirc; Boubaker, Jalela; Kaabachi, Nazihab; Filali, AzzaaEuropean Journal of Gastroenterology & Hepatology: March 2010 - Volume 22 - Issue 3 - pp 340-345 doi: 10.1097/MEG.0b013e32832bab49 Original Articles: Inflammatory Bowel Disease Abstract Author Information Abstract Objectives: Fecal calprotectin seems to have a diagnostic precision in predicting relapse in quiescent ulcerative colitis patients. However, the data remain controversial in Crohn's disease. The aim of this study was to prospectively evaluate the role of fecal calprotectin as a predictive marker for 1-year follow-up in patients with asymptomatic Crohn's disease. Methods: Fifty-three Crohn's disease patients in clinical remission were consecutively included providing at the beginning of the study a single stool sample as well as a blood sample and regularly followed-up for 12 months. Fecal calprotectin level was measured using a commercially available enzyme-linked immunoassay. Results: Among 53 patients, 10 (18.9%) developed clinical relapse during the 12-month follow-up period. Median fecal calprotectin level was significantly higher in relapse group patients compared with that in nonrelapse group (380.5 vs. 155 μg/g, P<0.001). With a cutoff value of 340 μg/g fecal calprotectin gave sensitivity of 80% and specificity of 90.7% in predicting clinical relapse. Fecal calprotectin level greater that 340 μg/g gave an 18-fold higher risk to develop relapse (log rank P<0.001) and was found to be an independent predictive factor of relapse (P=0.02). Conclusion: Fecal calprotectin seems to be a reliable marker of relapse in quiescent Crohn's disease patients. Author Information aDepartment of Gastroenterology A bLaboratory of Biochemistry, Rabta Hospital cDepartment of Statistics, Medical University, Tunis, Tunisia Correspondence to Lamia Kallel, Department of Gastroenterology A, Rabta Hospital, Jabbari 1007, Tunis, Tunisia Tel: +216 98 33 39 37; e-mail: Lamia_kallel@yahoo.fr Received 17 January 2009 Accepted 16 March 2009 © 2010 Lippincott Williams & Wilkins, Inc.